Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with juvenile dermatomyositis: a real-world multicentre study

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorUniv Med Ctr Utrecht-
Autor(es): dc.contributorUniv Fed Parana-
Autor(es): dc.contributorUniversidade de São Paulo (USP)-
Autor(es): dc.contributorUniversidade Federal de São Paulo (UNIFESP)-
Autor(es): dc.contributorHosp Estadual Infantil Nossa da Senhora-
Autor(es): dc.contributorUniversidade Federal do Rio de Janeiro (UFRJ)-
Autor(es): dc.contributorUniversidade do Estado do Rio de Janeiro (UERJ)-
Autor(es): dc.contributorHosp Infantil Albert Sabin-
Autor(es): dc.contributorUniv Florida-
Autor(es): dc.contributorHosp Crianca Brasilia Jose Alencar-
Autor(es): dc.contributorUniversidade Estadual de Campinas (UNICAMP)-
Autor(es): dc.contributorUniversidade Estadual Paulista (Unesp)-
Autor(es): dc.contributorNatl Inst Publ Hlth & Environm RIVM-
Autor(es): dc.contributorHosp Canc Barretos-
Autor(es): dc.creatorGrein, Ingrid Herta Rotstein-
Autor(es): dc.creatorPinto, Natalia Balera Ferreira-
Autor(es): dc.creatorGroot, Noortje-
Autor(es): dc.creatorMartins, Camila Bertini-
Autor(es): dc.creatorLobo, Aline-
Autor(es): dc.creatorAikawa, Nadia Emi-
Autor(es): dc.creatorBarbosa, Cassia-
Autor(es): dc.creatorTerreri, Maria Teresa-
Autor(es): dc.creatorFraga, Aline Coelho Moreira da-
Autor(es): dc.creatorOliveira, Sheila Knupp Feitosa de-
Autor(es): dc.creatorSztajnbok, Flavio-
Autor(es): dc.creatorPaim Marques, Luciana B.-
Autor(es): dc.creatorIslabao, Aline Garcia-
Autor(es): dc.creatorAppenzeller, Simone-
Autor(es): dc.creatorBica, Blanca-
Autor(es): dc.creatorOliveira Sato, Juliana de [UNESP]-
Autor(es): dc.creatorMagalhaes, Claudia Saad [UNESP]-
Autor(es): dc.creatorFerriani, Virginia-
Autor(es): dc.creatorPasmans, Hella-
Autor(es): dc.creatorSchepp, Rutger-
Autor(es): dc.creatorvan der Klis, Fiona-
Autor(es): dc.creatorRoock, Sytze de-
Autor(es): dc.creatorWulffraat, Nico-
Autor(es): dc.creatorPileggi, Gecilmara Salviato-
Data de aceite: dc.date.accessioned2022-02-22T00:57:12Z-
Data de disponibilização: dc.date.available2022-02-22T00:57:12Z-
Data de envio: dc.date.issued2021-06-25-
Data de envio: dc.date.issued2021-06-25-
Data de envio: dc.date.issued2020-11-10-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.1186/s12969-020-00479-w-
Fonte completa do material: dc.identifierhttp://hdl.handle.net/11449/209646-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/209646-
Descrição: dc.descriptionBackground: Concerns about the safety and efficacy of vaccines in patients with autoimmune diseases (AID) have led to contradictions and low vaccination coverage in this population, who are at a higher risk of infections, including by human papillomavirus (HPV). Although HPV vaccines have been recommended for immunocompromised patients, there is still a lack of data to support its use for AID patients, such as juvenile dermatomyositis (JDM) patients. The aim of this study was to assess the safety and immunogenicity of the quadrivalent HPV (qHPV) vaccine in a cohort of JDM patients. Methods: JDM patients aged from 9 to 20 years and healthy controls (HC) were enrolled to receive a 3-dose schedule of qHPV vaccine from March/2014 to March/2016. Study visits were performed before the first dose, 1 month after the second and third doses, and 6 months after the third dose. Participants completed a diary of possible adverse events for 14 days following each dose of vaccination (AEFV). Disease activity and current therapy were analyzed at each visit for JDM patients. In addition, serum samples from all participants were collected to test antibody concentrations against HPV16 and 18 at each visit. Participant recruitment was conducted in ten Brazilian centres. From 47 eligible JDM patients and 41 HC, 42 and 35, respectively, completed the 3-dose schedule of the vaccine, given that five JDM patients and two HC had received doses prior to their inclusion in the study. Results: The AEFVs presented by the participants were mild and in general did not differ between JDM and HC groups. No severe AEFVs were related to the vaccination. Disease activity was stable, or even improved during the follow-up. One month after the third dose of the vaccine the JDM group presented seropositivity of 100% for HPV16 and 97% for HPV18, similarly to the HC group, who presented 100% for both serotypes (p = 1.000). Six months after the third dose the seropositivity for the patient group was 94% for both HPV types. Conclusions: The HPV vaccination in this cohort of JDM patients was safe and immunogenic. Since the seropositivity against HPV16 and 18 was very high after the 3-dose schedule, this regimen should be recommended for JDM patients.-
Descrição: dc.descriptionUniv Med Ctr Utrecht, Wilhelmina Childrens Hosp, Dept Paediat Immunol & Rheumatol, Utrecht, Netherlands-
Descrição: dc.descriptionUniv Fed Parana, Hosp Clin, Dept Pediat, Gen Carneiro St 68,181, BR-80060900 Curitiba, Parana, Brazil-
Descrição: dc.descriptionUniv Sao Paulo, Fac Med Ribeirao Preto, Dept Paediat, Sao Paulo, Brazil-
Descrição: dc.descriptionUniv Fed Sao Paulo, Dept Prevent Med, Sao Paulo, Brazil-
Descrição: dc.descriptionUniv Sao Paulo, Fac Med, Hosp Clin, Dept Paediat Rheumatol,Inst Crianca, Sao Paulo, Brazil-
Descrição: dc.descriptionUniv Fed Sao Paulo, Dept Paediat Rheumatol, Sao Paulo, Brazil-
Descrição: dc.descriptionHosp Estadual Infantil Nossa da Senhora, Dept Paediat Rheumatol, Vitoria, ES, Brazil-
Descrição: dc.descriptionUniv Fed Rio de Janeiro, Inst Puericultura & Pediat Martagao Gesteira IPPM, Dept Paediat Rheumatol, Rio De Janeiro, Brazil-
Descrição: dc.descriptionUniv Estado Rio De Janeiro, Dept Paediat Rheumatol, Rio De Janeiro, Brazil-
Descrição: dc.descriptionHosp Infantil Albert Sabin, Dept Paediat Rheumatol, Fortaleza, Ceara, Brazil-
Descrição: dc.descriptionUniv Florida, Dept Paediat Immunol & Rheumatol, Coll Med, Gainesville, FL 32611 USA-
Descrição: dc.descriptionHosp Crianca Brasilia Jose Alencar, Dept Paediat Rheumatol, Brasilia, DF, Brazil-
Descrição: dc.descriptionUniv Estadual Campinas, Dept Paediat Rheumatol, Sao Paulo, Brazil-
Descrição: dc.descriptionUniv Fed Rio de Janeiro, Dept Paediat Rheumatol, Rio De Janeiro, Brazil-
Descrição: dc.descriptionUniv Estadual Paulista, Dept Paediat Rheumatol, Botucatu, SP, Brazil-
Descrição: dc.descriptionUniv Sao Paulo, Fac Med Ribeirao Preto, Dept Paediat Rheumatol, Sao Paulo, Brazil-
Descrição: dc.descriptionNatl Inst Publ Hlth & Environm RIVM, Ctr Infect Dis Control, Bilthoven, Netherlands-
Descrição: dc.descriptionHosp Canc Barretos, Fac Ciencias Saude Dr Paulo Prata FACISB, Sao Paulo, Brazil-
Descrição: dc.descriptionHosp Canc Barretos, Inst Ensino & Pesquisa IEP, Sao Paulo, Brazil-
Descrição: dc.descriptionUniv Estadual Paulista, Dept Paediat Rheumatol, Botucatu, SP, Brazil-
Formato: dc.format12-
Idioma: dc.languageen-
Publicador: dc.publisherBmc-
Relação: dc.relationPediatric Rheumatology-
???dc.source???: dc.sourceWeb of Science-
Palavras-chave: dc.subjectJuvenile dermatomyositis-
Palavras-chave: dc.subjectQuadrivalent HPV vaccine-
Palavras-chave: dc.subjectSafety-
Palavras-chave: dc.subjectImmunogenicity-
Título: dc.titleSafety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with juvenile dermatomyositis: a real-world multicentre study-
Tipo de arquivo: dc.typelivro digital-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.